Reven’s scientific research team has an ongoing commitment to compile and review RJX patient and study data to grow in our understanding of RJX. As an important part of this process, the team has spent countless hours scouring scientific literature to understand the pathology that RJX is positioned to influence. To organize this effort, Reven researchers have categorized candidate modalities as they relate to multiple disease states to further inform development of future dosing strategies, signals of interest, clinical plans, and future opportunities for variants built on the platform. A working list of diseases of interest are listed in alphabetical order and grouped by modality below.